MeiraGTx: Funding, Investors & Team (Sep 2026)
MeiraGTx is committed to the development and commercialization of innovative gene therapy products to transform the lives of patients suffering from acquired and inherited disorders. We are a vertically integrated, clinical stage gene therapy company with five ongoing clinical programs and a broad pipeline of preclinical and research programs. We have core capabilities in viral vector design and optimization and gene therapy manufacturing as well as a potentially transformative gene regulation technology. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.
MeiraGTx has raised $175M across 2 funding rounds on record, the most recent an undisclosed round of $100M announced in Apr 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
MeiraGTx Company Profile and Key Stats
Latest funding round on record: Apr 2026.
MeiraGTx Funding Rounds
MeiraGTx raised $75.0M in a Post-IPO Debt announced in Aug 2022.
3.7 years later, an undisclosed round of $100M was announced in Apr 2026.
MeiraGTx Founders and Leadership Team
No contact details are on record for this team yet.
MeiraGTx Funding Compared to Other Biotechnology Startups
MeiraGTx's latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like MeiraGTx in Biotechnology and New York
Companies Similar to MeiraGTx
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
MeiraGTx Funding FAQs
What does MeiraGTx do?
MeiraGTx is committed to the development and commercialization of innovative gene therapy products to transform the lives of patients suffering from acquired and inherited disorders. We are a vertically integrated, clinical stage gene therapy company with five ongoing clinical programs and a broad pipeline of preclinical and research programs. We have core capabilities in viral vector design and optimization and gene therapy manufacturing as well as a potentially transformative gene regulation technology. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.
How much funding has MeiraGTx raised?
MeiraGTx has raised $175M across 2 rounds on record. The most recent is an undisclosed round of $100M announced in Apr 2026.
When did MeiraGTx last raise funding?
MeiraGTx's most recent funding round on record is an undisclosed round of $100M, announced in Apr 2026.
Who founded MeiraGTx?
FundedIQ lists Zandy Forbes (Founder) at MeiraGTx.
Who is the CEO of MeiraGTx?
Alexandria Forbes is listed as CEO at MeiraGTx.
Where is MeiraGTx headquartered?
MeiraGTx is based in New York, United States.
How many employees does MeiraGTx have?
MeiraGTx is in the 11-50 employee band.
How does MeiraGTx's funding compare to other Biotechnology startups?
MeiraGTx's latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's MeiraGTx Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for MeiraGTx is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.